Biomarkers for the prognosis of ICI therapy are a provocative topic in the era of cancer immunotherapy, and multiple biomarkers and mechanisms related to sensitivity to ICI therapy have been confirmed.15 With the development of targeted sequencing, it is known that the status of TMB and MMR, as well as the expression of PD-L1, serve as compelling biomarkers in ICI therapy.4–6,16 However, novel biomarkers still need to be further explored given the limitations of regular biomarkers. The gene discussed is CD274; the disease is cancer.